Literature DB >> 7789380

Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations.

A J Marian1, A Mares, D P Kelly, Q T Yu, A B Abchee, R Hill, R Roberts.   

Abstract

BACKGROUND: Recent identification of mutations in the beta-myosin heavy chain gene (MYH7), a major responsible gene for HCM, has provided the opportunity to characterize genotype-phenotype correlation in HCM families. In this study we analysed the phenotypic expression of two beta-myosin heavy chain (beta MHC) mutations in three unrelated HCM families.
METHODS: Living individuals from three unrelated HCM families (Families 1, 2, and 3) were screened by history, physical examination, electrocardiography, and two-dimensional echocardiography. Blood was collected from all individuals for DNA extraction. Polymerase chain reaction (PCR), restriction endonuclease digestion and chemical cleavage were utilized for detection of mutations. All mutations were confirmed by sequence analysis.
RESULTS: Identification of mutations: A missense mutation in exon 13 of the beta MHC gene (Arg403 Gln) was detected in HCM patients from Families 1 and 2. PCR amplification of the exon 13 DNA, followed by Ddel digestion of the PCR product and gel electrophoresis, showed two fragments of 84 and 70 bp in normal individuals and four fragments of 84, 70, 52 and 32 bp in HCM patients. Sequence analysis showed substitution of an adenine for guanine at coding position 1208. In Family 3, a missense mutation in exon 16 of the beta MHC gene (Val606 Met) was detected in HCM patients. Chemical cleavage of the PCR products showed an uncleaved product of 337 bp in the normal individuals, while in the affected individuals, in addition to the uncleaved product, a 90 bp cleaved product was also detected, indicating the presence of a mismatch in one allele. Sequence analysis showed substitution of an adenine for guanine in coding position 1817. CLINICAL CHARACTERISTICS: Seven members of Family 1 had HCM, of whom five are alive. One patient died from sudden cardiac death (SCD) and another from recurrent cerebral emboli. In Family 2, 15 individuals had HCM of whom nine have died, seven from SCD. The mean age at the time of SCD was 33 years. The third family is comprised of 11 affected individuals and one obligate carrier, of whom one patient died at age 17 from progressive heart failure. Two additional individuals in this family have also succumbed to SCD to age 60. A variety of clinical and echocardiographic manifestations of HCM were present in each family. Logrank test of Kaplan-Meier survival curves indicates that Arg403 Gln mutation was associated with a poor prognosis in HCM families as compared to Val606 Met (P = 0.034).
CONCLUSIONS: beta MHC mutations despite showing variable clinical and echocardiographic manifestations of HCM are predictors of survival in HCM families.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789380     DOI: 10.1093/oxfordjournals.eurheartj.a060920

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  21 in total

Review 1.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 2.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

3.  From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy.

Authors:  S L Van Driest; B J Maron; M J Ackerman
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

4.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

Review 5.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 6.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

7.  Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.

Authors:  O Roopnarine; L A Leinwand
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

8.  A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies.

Authors:  Nigel F Clarke; Kimberly Amburgey; James Teener; Sandra Camelo-Piragua; Akanchha Kesari; Jaya Punetha; Leigh B Waddell; Mark Davis; Nigel G Laing; Nicole Monnier; Kathryn N North; Eric P Hoffman; James J Dowling
Journal:  Neuromuscul Disord       Date:  2013-03-09       Impact factor: 4.296

9.  MYBPC3 gene variations in hypertrophic cardiomyopathy patients in India.

Authors:  Reena R Tanjore; Advithi Rangaraju; P G Kerkar; Narsimhan Calambur; Pratibha Nallari
Journal:  Can J Cardiol       Date:  2008-02       Impact factor: 5.223

10.  Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice.

Authors:  L Oberst; G Zhao; J T Park; R Brugada; L H Michael; M L Entman; R Roberts; A J Marian
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.